Hari Shyam

Hari Shyam

Auto-generated profile, based on publicly available information

Hari Shyam

Mehrotra Pathology Pvt. Ltd, Lucknow, Uttar Pradesh, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Phytomedicine
Verified
Journal Article
Closed access
SKShweta Kaushik
Shweta Kaushik
HSHari Shyam
Hari Shyam
RSRamesh Sharma
Ramesh Sharma
ABAnil K. Balapure
Anil K. Balapure

1 January 2016 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ABAnil K Balapure
Anil K Balapure
SKShweta Kaushik
Shweta Kaushik
HSHari Shyam
Hari Shyam
RSRamesh Sharma
Ramesh Sharma
Objectives: Despite the progress in the diagnosis and treatment of breast cancer, it remains a major health problem in women. Natural flavones along with chemotherapeutic agents enhance therapeutic response and minimize toxicity of chemical agents. Centchroman (CC) colloquially called as ormeloxifene, is a nonsteroidal oral contraceptive categorized as selective estrogen receptor modulator with anti-breast cancer activity. Genistein (GN), an isoflavone found mainly in soy products possesses anti-cancerous potential against a number of cancers including breast. The present study aims at investigating the combination of CC and GN in human breast cancer cell lines (HBCCs). Materials and Methods: Cytotoxic effect of CC and GN separately and in combination were assessed by sulforhodamine B (SRB) assay in MDA MB-231, MDA MB-468, MCF-7, T-47D HBCCs, and nontumorigenic human mammary epithelial cell (HMEC) MCF-10A. The drug interaction was analyzed using CompuSyn software through which combination index and dose reduction index were generated. Results: Combination of CC plus GN exerts significantly higher cytotoxicity compared to each drug per se in HBCCs, whereas HMEC-MCF-10A remains unaffected. Conclusion: On an overall basis, the drugs in combination enhanced cell killing in malignant cells. Therefore, the combination of CC with GN may offer a novel approach for the breast cancer.

29 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNeetu Singh
Neetu Singh
DZDeeba Zaidi
Deeba Zaidi
HSHari Shyam
Hari Shyam
RSRamesh Sharma
Ramesh Sharma
ABAnil Kumar Balapure
Anil Kumar Balapure
Polyphenols as “sensitizers” together with cytotoxic drugs as “inducers” cooperate to trigger apoptosis in various cancer cells. Hence, their combination having similar mode of mechanism may be a novel approach to enhance the efficacy of inducers. Additionally, this will also enable to achieve the physiological concentrations facilitating significant increase in the activity at concentrations which the compound can individually provide. Here we propose that polyphenols (Resveratrol (RES) and Curcumin (CUR)) pre-treatment may sensitize MCF-7/MDA MB-231 (Human Breast Cancer Cells, HBCCs) to Centchroman (CC, antineoplastic agent). 6 h pre-treated cells with 10 µM RES/CUR and 100 µM RES/30 µM CUR doses, followed by 10 µM CC for 18 h were investigated for Ser-167 ER-phosphorylation, cell cycle arrest, redox homeostasis, stress activated protein kinase (SAPKs: JNK and p38 MAPK) pathways and downstream apoptosis effectors. Low dose RES/CUR enhances the CC action through ROS mediated JNK/p38 as well as mitochondrial pathway in MCF-7 cells. However, RES/CUR sensitization enhanced apoptosis in p53 mutant MDA MB-231 cells without/with involvement of ROS mediated JNK/p38 adjunct to Caspase-9. Contrarily, through high dose sensitization in CC treated cells, the parameters remained unaltered as in polyphenols alone. We conclude that differential sensitization of HBCCs with low dose polyphenol augments apoptotic efficacy of CC. This may offer a novel approach to achieve enhanced action of CC with concomitant reduction of side effects enabling improved management of hormone-dependent breast cancer.

21 February 2017 in Regenerative Medicine
Verified
Journal Article
Closed access
HSHari Shyam
Hari Shyam
SSSatyendra K Singh
Satyendra K Singh
RKRavi Kant
Ravi Kant
SSShailendra K Saxena
Shailendra K Saxena

13 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
NSNeetu Singh
Neetu Singh
ATAnil Kumar Tripathi
Anil Kumar Tripathi
DSDinesh Kumar Sahu
Dinesh Kumar Sahu
AMArchana Mishra
Archana Mishra
MLMargaret Linan
Margaret Linan
RKRavi Kant
Ravi Kant
Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia

7 February 2017 in Apoptosis
Verified
Journal Article
Closed access
PDF file
HSHari Shyam
Hari Shyam
NSNeetu Singh
Neetu Singh
SKShweta Kaushik
Shweta Kaushik
RSRamesh Sharma
Ramesh Sharma
ABAnil K. Balapure
Anil K. Balapure